Chris Cargill, Sosei Heptares CEO
August 2, 2022 07:07 AM EDT
Deals
R&D

With some neu­ro tar­gets in mind, Ab­b­Vie gets So­sei's drug dis­cov­ery en­gine churn­ing again

Amber Tong

Ab­b­Vie has got more work for So­sei Hep­tares.

A year and a half af­ter break­ing off a lega­cy Al­ler­gan pact in­volv­ing a slate of So­sei …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

J&J takes 340B fight with fed­er­al gov­ern­ment to court

Adap­ti­m­mune's sec­ond T cell re­cep­tor cell ther­a­py for rare sar­co­mas pass­es piv­otal test

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times